双相I型障碍初始症状严重程度与奥氮平疗效:五项安慰剂对照研究个体参与者数据荟萃分析
该研究基于五项双盲随机安慰剂对照试验的939例急性躁狂患者个体数据,分析基线严重程度对奥氮平疗效的影响。结果显示基线严重程度与治疗交互作用显著,基线越重奥氮平与安慰剂的YMRS减分差异越大。奥氮平对全症状严重度谱患者均有获益,但轻症患者获益较小而副作用相同。
要点
- 基线严重程度与治疗存在显著交互作用,基线越重奥氮平疗效优势越明显
- 轻症患者奥氮平获益较小但副作用相同,需权衡获益风险比
核心结论
- 奥氮平对急性躁狂全症状严重度谱患者均可预期获益,但轻症患者疗效获益较小而副作用相同。
研究设计与样本
- 个体参与者数据荟萃分析,纳入5项双盲随机安慰剂对照试验共939例双相I型障碍急性躁狂患者(奥氮平552例,安慰剂387例)。
关键数值与推荐
- 采用Young躁狂评定量表(YMRS,范围0-60)评估基线及3周内变化。
- 使用8种复杂度递增的竞争性混合效应模型重复测量分析。
临床怎么用
- 临床医生与患者应仔细考虑奥氮平的获益风险比及其长期预防复发的额外效应。
局限性
- 结果对其他抗精神病药、试验设计及躯体疾病的普适性尚待确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of antipsychotics across the initial severity range in patients with acute mania remains unclear. Therefore, we examined the influence of baseline severity on the efficacy of olanzapine. METHODS: We did an individual participant data meta-analysis of double-blind, randomised controlled trials that compared olanzapine with placebo, identified through searches of the ClinicalStudyRequest.com database on Feb 2, 2016. We included patients with acute mania associated with bipolar I disorder. We examined the association between baseline and change scores on the Young Mania Rating Scale (YMRS; range 0-60) up to 3 weeks for olanzapine versus placebo groups using eight increasingly complex competing mixed-effects models for repeated measures. FINDINGS: We identified 33 reports, five (15%) of which were eligible and contained data for 939 patients (552 received olanzapine; 387 received placebo). The interaction between baseline severity and treatment was significant (β=0·22, 95% CI 0·05-0·39; p=0·013). The greater the baseline severity, the greater the magnitude of the differences between olanzapine and placebo was expected. The mean estimated YMRS scores were reduced at 3 weeks in both groups, but were greater with olazapine than placebo by 2·56 points for patients with a baseline score of 20-25 (9·26 for olanzapine vs 6·70 for placebo; effect size 0·35, 95% CI 0·11-0·60), by 4·74 points for a baseline score of 25-35 (14·25 vs 9·51; 0·58, 0·34-0·86), and by 8·01 points for a baseline score of 35-60 (21·72 vs 13·71; 0·70, 0·31-1·23). INTERPRETATION: Benefits of olanzapine can be expected for patients across the full spectrum of symptom severity who are likely to be treated for acute mania. Less severely ill patients seem to benefit less in terms of olanzapine efficacy, but still experience the same side-effects as more severely ill patients. Thus, clinicians and patients should carefully consider the benefit-to-risk ratio of olanzapine and its additional, prophylactic effect against relapse in the long term. The generalisability of these results to other antipsychotics, trial designs, and medical conditions remains to be established. FUNDING: None.
引用
- Samara MT, Goldberg Y, Levine SZ, et al. Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry. 2017. PMID: 28939419. doi:10.1016/S2215-0366(17)30331-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。